Mydecine Innovations Group Inc.
Mydecine Innovations Group Inc. (MYCO.NE) Stock Competitors & Peer Comparison
See (MYCO.NE) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MYCO.NE | CA$0.35 | +0.00% | 21.4M | -0.54 | -CA$0.65 | N/A |
| CURA.CN | CA$5.22 | +9.21% | 4.1B | -6.07 | -CA$0.86 | N/A |
| BHC.TO | CA$7.49 | +7.15% | 2.6B | 12.10 | CA$0.58 | N/A |
| VRNO.CN | CA$6.32 | +6.76% | 2.2B | -5.40 | -CA$1.17 | N/A |
| CURA.TO | CA$2.95 | +6.50% | 2B | -6.00 | -CA$0.44 | N/A |
| GTII.CN | CA$8.68 | +8.50% | 1.8B | 11.92 | CA$0.66 | N/A |
| CRON.TO | CA$3.51 | +0.86% | 1.3B | -113.33 | -CA$0.03 | N/A |
| TRUL.CN | CA$7.74 | +4.59% | 1.2B | -8.81 | -CA$0.80 | N/A |
| TLRY.TO | CA$8.96 | +1.82% | 845.4M | -0.26 | -CA$32.51 | N/A |
| TER.CN | CA$2.38 | -0.42% | 804.8M | -1.33 | -CA$1.79 | N/A |
Stock Comparison
MYCO.NE vs CURA.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CURA.CN has a market cap of 4.1B. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while CURA.CN trades at CA$5.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CURA.CN's P/E ratio is -6.07. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to CURA.CN's ROE of -0.28%. Regarding short-term risk, MYCO.NE is less volatile compared to CURA.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check CURA.CN's competition here
MYCO.NE vs BHC.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, BHC.TO has a market cap of 2.6B. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while BHC.TO trades at CA$7.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas BHC.TO's P/E ratio is 12.10. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to BHC.TO's ROE of -0.20%. Regarding short-term risk, MYCO.NE is less volatile compared to BHC.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check BHC.TO's competition here
MYCO.NE vs VRNO.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, VRNO.CN has a market cap of 2.2B. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while VRNO.CN trades at CA$6.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas VRNO.CN's P/E ratio is -5.40. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to VRNO.CN's ROE of -0.30%. Regarding short-term risk, MYCO.NE is less volatile compared to VRNO.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check VRNO.CN's competition here
MYCO.NE vs CURA.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CURA.TO has a market cap of 2B. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while CURA.TO trades at CA$2.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CURA.TO's P/E ratio is -6.00. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to CURA.TO's ROE of -0.30%. Regarding short-term risk, MYCO.NE is less volatile compared to CURA.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check CURA.TO's competition here
MYCO.NE vs GTII.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, GTII.CN has a market cap of 1.8B. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while GTII.CN trades at CA$8.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas GTII.CN's P/E ratio is 11.92. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to GTII.CN's ROE of +0.06%. Regarding short-term risk, MYCO.NE is less volatile compared to GTII.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check GTII.CN's competition here
MYCO.NE vs CRON.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CRON.TO has a market cap of 1.3B. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while CRON.TO trades at CA$3.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CRON.TO's P/E ratio is -113.33. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to CRON.TO's ROE of -0.01%. Regarding short-term risk, MYCO.NE is less volatile compared to CRON.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check CRON.TO's competition here
MYCO.NE vs TRUL.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, TRUL.CN has a market cap of 1.2B. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while TRUL.CN trades at CA$7.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas TRUL.CN's P/E ratio is -8.81. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to TRUL.CN's ROE of -0.10%. Regarding short-term risk, MYCO.NE is less volatile compared to TRUL.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check TRUL.CN's competition here
MYCO.NE vs TLRY.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, TLRY.TO has a market cap of 845.4M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while TLRY.TO trades at CA$8.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas TLRY.TO's P/E ratio is -0.26. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to TLRY.TO's ROE of -1.06%. Regarding short-term risk, MYCO.NE is less volatile compared to TLRY.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check TLRY.TO's competition here
MYCO.NE vs TER.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, TER.CN has a market cap of 804.8M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while TER.CN trades at CA$2.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas TER.CN's P/E ratio is -1.33. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to TER.CN's ROE of -0.73%. Regarding short-term risk, MYCO.NE is less volatile compared to TER.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check TER.CN's competition here
MYCO.NE vs GUD.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, GUD.TO has a market cap of 724.8M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while GUD.TO trades at CA$7.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas GUD.TO's P/E ratio is -146.00. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to GUD.TO's ROE of -0.01%. Regarding short-term risk, MYCO.NE is less volatile compared to GUD.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check GUD.TO's competition here
MYCO.NE vs DHT-U.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, DHT-U.TO has a market cap of 674.9M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while DHT-U.TO trades at CA$12.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas DHT-U.TO's P/E ratio is -13.46. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to DHT-U.TO's ROE of -0.11%. Regarding short-term risk, MYCO.NE and DHT-U.TO have similar daily volatility (0.00).Check DHT-U.TO's competition here
MYCO.NE vs DHT-UN.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, DHT-UN.TO has a market cap of 596.8M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while DHT-UN.TO trades at CA$17.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas DHT-UN.TO's P/E ratio is -12.60. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to DHT-UN.TO's ROE of -0.11%. Regarding short-term risk, MYCO.NE is less volatile compared to DHT-UN.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check DHT-UN.TO's competition here
MYCO.NE vs VRNO.NE Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, VRNO.NE has a market cap of 479.5M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while VRNO.NE trades at CA$1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas VRNO.NE's P/E ratio is -1.35. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to VRNO.NE's ROE of -0.30%. Regarding short-term risk, MYCO.NE is less volatile compared to VRNO.NE. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check VRNO.NE's competition here
MYCO.NE vs CPH.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CPH.TO has a market cap of 465.3M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while CPH.TO trades at CA$18.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CPH.TO's P/E ratio is 12.65. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to CPH.TO's ROE of +0.24%. Regarding short-term risk, MYCO.NE is less volatile compared to CPH.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check CPH.TO's competition here
MYCO.NE vs CCHW.NE Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CCHW.NE has a market cap of 407.2M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while CCHW.NE trades at CA$1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CCHW.NE's P/E ratio is -3.52. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to CCHW.NE's ROE of -1.07%. Regarding short-term risk, MYCO.NE is less volatile compared to CCHW.NE. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check CCHW.NE's competition here
MYCO.NE vs CL.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CL.CN has a market cap of 370.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while CL.CN trades at CA$1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CL.CN's P/E ratio is -2.08. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to CL.CN's ROE of -0.32%. Regarding short-term risk, MYCO.NE is less volatile compared to CL.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check CL.CN's competition here
MYCO.NE vs ACB.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, ACB.TO has a market cap of 245.6M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while ACB.TO trades at CA$4.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas ACB.TO's P/E ratio is -2.91. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to ACB.TO's ROE of -0.01%. Regarding short-term risk, MYCO.NE is less volatile compared to ACB.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check ACB.TO's competition here
MYCO.NE vs OGI.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, OGI.TO has a market cap of 238.6M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while OGI.TO trades at CA$1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas OGI.TO's P/E ratio is 11.67. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to OGI.TO's ROE of +0.05%. Regarding short-term risk, MYCO.NE is less volatile compared to OGI.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check OGI.TO's competition here
MYCO.NE vs CCHW.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CCHW.CN has a market cap of 228.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while CCHW.CN trades at CA$0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CCHW.CN's P/E ratio is -0.41. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to CCHW.CN's ROE of -1.08%. Regarding short-term risk, MYCO.NE and CCHW.CN have similar daily volatility (0.00).Check CCHW.CN's competition here
MYCO.NE vs TSND.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, TSND.TO has a market cap of 228.3M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while TSND.TO trades at CA$0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas TSND.TO's P/E ratio is -5.29. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to TSND.TO's ROE of -0.73%. Regarding short-term risk, MYCO.NE is less volatile compared to TSND.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check TSND.TO's competition here
MYCO.NE vs WEED.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, WEED.TO has a market cap of 218.1M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while WEED.TO trades at CA$1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas WEED.TO's P/E ratio is -0.65. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to WEED.TO's ROE of -0.53%. Regarding short-term risk, MYCO.NE is less volatile compared to WEED.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check WEED.TO's competition here
MYCO.NE vs TH.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, TH.TO has a market cap of 205.5M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while TH.TO trades at CA$4.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas TH.TO's P/E ratio is -17.19. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to TH.TO's ROE of +0.47%. Regarding short-term risk, MYCO.NE is less volatile compared to TH.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check TH.TO's competition here
MYCO.NE vs CRDL.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CRDL.TO has a market cap of 191M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while CRDL.TO trades at CA$1.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CRDL.TO's P/E ratio is -4.17. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to CRDL.TO's ROE of -2.18%. Regarding short-term risk, MYCO.NE is less volatile compared to CRDL.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check CRDL.TO's competition here
MYCO.NE vs XLY.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, XLY.TO has a market cap of 175.3M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while XLY.TO trades at CA$0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas XLY.TO's P/E ratio is 4.33. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to XLY.TO's ROE of +0.27%. Regarding short-term risk, MYCO.NE is less volatile compared to XLY.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check XLY.TO's competition here
MYCO.NE vs CWEB.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CWEB.TO has a market cap of 141.9M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while CWEB.TO trades at CA$1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CWEB.TO's P/E ratio is -4.68. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to CWEB.TO's ROE of -1.20%. Regarding short-term risk, MYCO.NE is less volatile compared to CWEB.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check CWEB.TO's competition here
MYCO.NE vs BHSC.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, BHSC.CN has a market cap of 137.8M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while BHSC.CN trades at CA$7.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas BHSC.CN's P/E ratio is -4.37. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to BHSC.CN's ROE of -2.06%. Regarding short-term risk, MYCO.NE is less volatile compared to BHSC.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check BHSC.CN's competition here
MYCO.NE vs HLS.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, HLS.TO has a market cap of 136.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while HLS.TO trades at CA$4.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas HLS.TO's P/E ratio is -8.09. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to HLS.TO's ROE of -0.19%. Regarding short-term risk, MYCO.NE is less volatile compared to HLS.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check HLS.TO's competition here
MYCO.NE vs JUSH.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, JUSH.CN has a market cap of 120M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while JUSH.CN trades at CA$0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas JUSH.CN's P/E ratio is -1.33. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to JUSH.CN's ROE of +0.89%. Regarding short-term risk, MYCO.NE is less volatile compared to JUSH.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check JUSH.CN's competition here
MYCO.NE vs GRIN.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, GRIN.CN has a market cap of 97.3M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while GRIN.CN trades at CA$0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas GRIN.CN's P/E ratio is 9.75. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to GRIN.CN's ROE of +0.28%. Regarding short-term risk, MYCO.NE is less volatile compared to GRIN.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check GRIN.CN's competition here
MYCO.NE vs MDP.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, MDP.TO has a market cap of 94.3M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while MDP.TO trades at CA$3.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas MDP.TO's P/E ratio is -97.33. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to MDP.TO's ROE of -0.00%. Regarding short-term risk, MYCO.NE is less volatile compared to MDP.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check MDP.TO's competition here
MYCO.NE vs GDNS.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, GDNS.CN has a market cap of 91M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while GDNS.CN trades at CA$0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas GDNS.CN's P/E ratio is -2.74. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to GDNS.CN's ROE of -0.46%. Regarding short-term risk, MYCO.NE and GDNS.CN have similar daily volatility (0.00).Check GDNS.CN's competition here
MYCO.NE vs TGOD.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, TGOD.CN has a market cap of 62.2M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while TGOD.CN trades at CA$0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas TGOD.CN's P/E ratio is -3.28. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to TGOD.CN's ROE of -0.90%. Regarding short-term risk, MYCO.NE and TGOD.CN have similar daily volatility (0.00).Check TGOD.CN's competition here
MYCO.NE vs PLTH.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, PLTH.CN has a market cap of 60.2M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while PLTH.CN trades at CA$0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas PLTH.CN's P/E ratio is -0.66. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to PLTH.CN's ROE of -0.81%. Regarding short-term risk, MYCO.NE is less volatile compared to PLTH.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check PLTH.CN's competition here
MYCO.NE vs BNXT.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, BNXT.CN has a market cap of 57.3M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while BNXT.CN trades at CA$0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas BNXT.CN's P/E ratio is -9.40. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to BNXT.CN's ROE of +0.77%. Regarding short-term risk, MYCO.NE is less volatile compared to BNXT.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check BNXT.CN's competition here
MYCO.NE vs VEXT.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, VEXT.CN has a market cap of 57M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while VEXT.CN trades at CA$0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas VEXT.CN's P/E ratio is -2.30. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to VEXT.CN's ROE of -0.23%. Regarding short-term risk, MYCO.NE is less volatile compared to VEXT.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check VEXT.CN's competition here
MYCO.NE vs STEM.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, STEM.CN has a market cap of 53.6M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while STEM.CN trades at CA$0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas STEM.CN's P/E ratio is -0.11. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to STEM.CN's ROE of -2.75%. Regarding short-term risk, MYCO.NE and STEM.CN have similar daily volatility (0.00).Check STEM.CN's competition here
MYCO.NE vs LEEF.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, LEEF.CN has a market cap of 42.6M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while LEEF.CN trades at CA$0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas LEEF.CN's P/E ratio is -2.09. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to LEEF.CN's ROE of +1.64%. Regarding short-term risk, MYCO.NE is less volatile compared to LEEF.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check LEEF.CN's competition here
MYCO.NE vs MRMD.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, MRMD.CN has a market cap of 39.8M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while MRMD.CN trades at CA$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas MRMD.CN's P/E ratio is -1.67. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to MRMD.CN's ROE of -0.25%. Regarding short-term risk, MYCO.NE is less volatile compared to MRMD.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check MRMD.CN's competition here
MYCO.NE vs HEXO.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, HEXO.TO has a market cap of 38.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while HEXO.TO trades at CA$0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas HEXO.TO's P/E ratio is -0.26. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to HEXO.TO's ROE of -2.06%. Regarding short-term risk, MYCO.NE is less volatile compared to HEXO.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check HEXO.TO's competition here
MYCO.NE vs CHM.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CHM.CN has a market cap of 37.2M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while CHM.CN trades at CA$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CHM.CN's P/E ratio is -5.00. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to CHM.CN's ROE of +0.78%. Regarding short-term risk, MYCO.NE and CHM.CN have similar daily volatility (0.00).Check CHM.CN's competition here
MYCO.NE vs CXXI.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CXXI.CN has a market cap of 36.6M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while CXXI.CN trades at CA$0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CXXI.CN's P/E ratio is -7.75. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to CXXI.CN's ROE of -0.12%. Regarding short-term risk, MYCO.NE is less volatile compared to CXXI.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check CXXI.CN's competition here
MYCO.NE vs IAN.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, IAN.CN has a market cap of 34.1M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while IAN.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas IAN.CN's P/E ratio is 0.50. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to IAN.CN's ROE of +0.50%. Regarding short-term risk, MYCO.NE and IAN.CN have similar daily volatility (0.00).Check IAN.CN's competition here
MYCO.NE vs INNO.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, INNO.CN has a market cap of 29.6M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while INNO.CN trades at CA$6.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas INNO.CN's P/E ratio is -5.78. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to INNO.CN's ROE of -0.72%. Regarding short-term risk, MYCO.NE is less volatile compared to INNO.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check INNO.CN's competition here
MYCO.NE vs MVMD.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, MVMD.CN has a market cap of 28.2M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while MVMD.CN trades at CA$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas MVMD.CN's P/E ratio is -4.00. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to MVMD.CN's ROE of -4.61%. Regarding short-term risk, MYCO.NE is less volatile compared to MVMD.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check MVMD.CN's competition here
MYCO.NE vs MMEN.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, MMEN.CN has a market cap of 27.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while MMEN.CN trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas MMEN.CN's P/E ratio is -0.13. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to MMEN.CN's ROE of -0.96%. Regarding short-term risk, MYCO.NE is less volatile compared to MMEN.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check MMEN.CN's competition here
MYCO.NE vs LABS.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, LABS.TO has a market cap of 27.3M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while LABS.TO trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas LABS.TO's P/E ratio is -2.17. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to LABS.TO's ROE of -0.20%. Regarding short-term risk, MYCO.NE is less volatile compared to LABS.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check LABS.TO's competition here
MYCO.NE vs YOUR.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, YOUR.CN has a market cap of 22.9M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while YOUR.CN trades at CA$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas YOUR.CN's P/E ratio is 8.50. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to YOUR.CN's ROE of -1.18%. Regarding short-term risk, MYCO.NE and YOUR.CN have similar daily volatility (0.00).Check YOUR.CN's competition here
MYCO.NE vs GWAY.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, GWAY.CN has a market cap of 22.6M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while GWAY.CN trades at CA$0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas GWAY.CN's P/E ratio is -17.00. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to GWAY.CN's ROE of -0.02%. Regarding short-term risk, MYCO.NE is less volatile compared to GWAY.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check GWAY.CN's competition here
MYCO.NE vs EPIC.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, EPIC.CN has a market cap of 20.6M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while EPIC.CN trades at CA$0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas EPIC.CN's P/E ratio is 8.75. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to EPIC.CN's ROE of +0.02%. Regarding short-term risk, MYCO.NE and EPIC.CN have similar daily volatility (0.00).Check EPIC.CN's competition here
MYCO.NE vs VIN.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, VIN.CN has a market cap of 20.2M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while VIN.CN trades at CA$0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas VIN.CN's P/E ratio is -0.67. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to VIN.CN's ROE of -0.79%. Regarding short-term risk, Volatility data is not available for a full comparison. MYCO.NE has daily volatility of 0.00 and VIN.CN has daily volatility of N/A.Check VIN.CN's competition here
MYCO.NE vs AVCN.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, AVCN.TO has a market cap of 18.8M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while AVCN.TO trades at CA$0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas AVCN.TO's P/E ratio is -15.00. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to AVCN.TO's ROE of -0.68%. Regarding short-term risk, MYCO.NE is less volatile compared to AVCN.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check AVCN.TO's competition here
MYCO.NE vs AYR-A.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, AYR-A.CN has a market cap of 18.1M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while AYR-A.CN trades at CA$0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas AYR-A.CN's P/E ratio is -0.03. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to AYR-A.CN's ROE of -0.65%. Regarding short-term risk, MYCO.NE is less volatile compared to AYR-A.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check AYR-A.CN's competition here
MYCO.NE vs CBST.NE Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CBST.NE has a market cap of 17.4M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while CBST.NE trades at CA$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CBST.NE's P/E ratio is -0.07. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to CBST.NE's ROE of +1.89%. Regarding short-term risk, MYCO.NE and CBST.NE have similar daily volatility (0.00).Check CBST.NE's competition here
MYCO.NE vs IMCC.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, IMCC.CN has a market cap of 17.2M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while IMCC.CN trades at CA$5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas IMCC.CN's P/E ratio is -2.68. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to IMCC.CN's ROE of -0.41%. Regarding short-term risk, MYCO.NE is less volatile compared to IMCC.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check IMCC.CN's competition here
MYCO.NE vs MRV.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, MRV.TO has a market cap of 15.4M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while MRV.TO trades at CA$1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas MRV.TO's P/E ratio is -19.29. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to MRV.TO's ROE of N/A. Regarding short-term risk, MYCO.NE is less volatile compared to MRV.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check MRV.TO's competition here
MYCO.NE vs RVV.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, RVV.CN has a market cap of 15.2M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while RVV.CN trades at CA$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas RVV.CN's P/E ratio is -1.17. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to RVV.CN's ROE of +9.00%. Regarding short-term risk, MYCO.NE and RVV.CN have similar daily volatility (0.00).Check RVV.CN's competition here
MYCO.NE vs EXM.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, EXM.CN has a market cap of 15.1M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while EXM.CN trades at CA$0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas EXM.CN's P/E ratio is -0.91. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to EXM.CN's ROE of -18.63%. Regarding short-term risk, MYCO.NE and EXM.CN have similar daily volatility (0.00).Check EXM.CN's competition here
MYCO.NE vs PWR.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, PWR.CN has a market cap of 15M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while PWR.CN trades at CA$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas PWR.CN's P/E ratio is 5.00. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to PWR.CN's ROE of -0.81%. Regarding short-term risk, MYCO.NE and PWR.CN have similar daily volatility (0.00).Check PWR.CN's competition here
MYCO.NE vs CHAL.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CHAL.CN has a market cap of 14.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while CHAL.CN trades at CA$0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CHAL.CN's P/E ratio is -2.25. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to CHAL.CN's ROE of +0.00%. Regarding short-term risk, MYCO.NE and CHAL.CN have similar daily volatility (0.00).Check CHAL.CN's competition here
MYCO.NE vs CTX.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CTX.TO has a market cap of 14M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while CTX.TO trades at CA$0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CTX.TO's P/E ratio is 37.00. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to CTX.TO's ROE of +0.03%. Regarding short-term risk, MYCO.NE is less volatile compared to CTX.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check CTX.TO's competition here
MYCO.NE vs RIV.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, RIV.CN has a market cap of 13.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while RIV.CN trades at CA$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas RIV.CN's P/E ratio is -0.21. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to RIV.CN's ROE of -0.49%. Regarding short-term risk, MYCO.NE and RIV.CN have similar daily volatility (0.00).Check RIV.CN's competition here
MYCO.NE vs LOBE.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, LOBE.CN has a market cap of 13.5M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while LOBE.CN trades at CA$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas LOBE.CN's P/E ratio is -1.75. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to LOBE.CN's ROE of +3.96%. Regarding short-term risk, MYCO.NE and LOBE.CN have similar daily volatility (0.00).Check LOBE.CN's competition here
MYCO.NE vs ORI.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, ORI.CN has a market cap of 11.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while ORI.CN trades at CA$0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas ORI.CN's P/E ratio is -2.11. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to ORI.CN's ROE of +0.09%. Regarding short-term risk, MYCO.NE and ORI.CN have similar daily volatility (0.00).Check ORI.CN's competition here
MYCO.NE vs BBM.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, BBM.CN has a market cap of 9.9M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while BBM.CN trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas BBM.CN's P/E ratio is -2.00. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to BBM.CN's ROE of -1.67%. Regarding short-term risk, MYCO.NE and BBM.CN have similar daily volatility (0.00).Check BBM.CN's competition here
MYCO.NE vs CNFA.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CNFA.CN has a market cap of 9.8M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while CNFA.CN trades at CA$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CNFA.CN's P/E ratio is -0.83. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to CNFA.CN's ROE of -7.84%. Regarding short-term risk, MYCO.NE and CNFA.CN have similar daily volatility (0.00).Check CNFA.CN's competition here
MYCO.NE vs OILS.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, OILS.CN has a market cap of 9.3M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while OILS.CN trades at CA$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas OILS.CN's P/E ratio is 5.50. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to OILS.CN's ROE of -0.08%. Regarding short-term risk, MYCO.NE and OILS.CN have similar daily volatility (0.00).Check OILS.CN's competition here
MYCO.NE vs VIVO.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, VIVO.TO has a market cap of 9.3M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while VIVO.TO trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas VIVO.TO's P/E ratio is -0.16. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to VIVO.TO's ROE of -0.78%. Regarding short-term risk, MYCO.NE is less volatile compared to VIVO.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check VIVO.TO's competition here
MYCO.NE vs CLSH.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CLSH.CN has a market cap of 8.1M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while CLSH.CN trades at CA$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CLSH.CN's P/E ratio is 3.50. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to CLSH.CN's ROE of +0.03%. Regarding short-term risk, MYCO.NE and CLSH.CN have similar daily volatility (0.00).Check CLSH.CN's competition here
MYCO.NE vs AH.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, AH.TO has a market cap of 8.1M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while AH.TO trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas AH.TO's P/E ratio is -0.22. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to AH.TO's ROE of -0.58%. Regarding short-term risk, MYCO.NE is less volatile compared to AH.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check AH.TO's competition here
MYCO.NE vs AVNT.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, AVNT.TO has a market cap of 7.9M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while AVNT.TO trades at CA$0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas AVNT.TO's P/E ratio is -0.78. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to AVNT.TO's ROE of -0.35%. Regarding short-term risk, MYCO.NE and AVNT.TO have similar daily volatility (0.00).Check AVNT.TO's competition here
MYCO.NE vs AUSA.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, AUSA.CN has a market cap of 7.8M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while AUSA.CN trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas AUSA.CN's P/E ratio is -0.11. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to AUSA.CN's ROE of -1.15%. Regarding short-term risk, MYCO.NE and AUSA.CN have similar daily volatility (0.00).Check AUSA.CN's competition here
MYCO.NE vs STHZ.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, STHZ.CN has a market cap of 7.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while STHZ.CN trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas STHZ.CN's P/E ratio is -0.10. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to STHZ.CN's ROE of +0.36%. Regarding short-term risk, MYCO.NE and STHZ.CN have similar daily volatility (0.00).Check STHZ.CN's competition here
MYCO.NE vs MOJO.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, MOJO.CN has a market cap of 7.5M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while MOJO.CN trades at CA$0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas MOJO.CN's P/E ratio is -5.36. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to MOJO.CN's ROE of -1.22%. Regarding short-term risk, MYCO.NE and MOJO.CN have similar daily volatility (0.00).Check MOJO.CN's competition here
MYCO.NE vs TRIP.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, TRIP.CN has a market cap of 7.4M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while TRIP.CN trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas TRIP.CN's P/E ratio is -1.75. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to TRIP.CN's ROE of -0.30%. Regarding short-term risk, MYCO.NE is less volatile compared to TRIP.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check TRIP.CN's competition here
MYCO.NE vs CLC.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CLC.CN has a market cap of 7.4M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while CLC.CN trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CLC.CN's P/E ratio is 3.00. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to CLC.CN's ROE of +0.08%. Regarding short-term risk, MYCO.NE and CLC.CN have similar daily volatility (0.00).Check CLC.CN's competition here
MYCO.NE vs SPR.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, SPR.CN has a market cap of 7.3M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while SPR.CN trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas SPR.CN's P/E ratio is -0.40. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to SPR.CN's ROE of +18.75%. Regarding short-term risk, MYCO.NE and SPR.CN have similar daily volatility (0.00).Check SPR.CN's competition here
MYCO.NE vs RWB.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, RWB.CN has a market cap of 7.1M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while RWB.CN trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas RWB.CN's P/E ratio is -0.14. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to RWB.CN's ROE of +0.23%. Regarding short-term risk, MYCO.NE and RWB.CN have similar daily volatility (0.00).Check RWB.CN's competition here
MYCO.NE vs HASH.V Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, HASH.V has a market cap of 6.9M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while HASH.V trades at CA$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas HASH.V's P/E ratio is 1.00. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to HASH.V's ROE of +0.14%. Regarding short-term risk, MYCO.NE and HASH.V have similar daily volatility (0.00).Check HASH.V's competition here
MYCO.NE vs SE.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, SE.CN has a market cap of 6.6M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while SE.CN trades at CA$0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas SE.CN's P/E ratio is 2.43. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to SE.CN's ROE of -73.98%. Regarding short-term risk, MYCO.NE and SE.CN have similar daily volatility (0.00).Check SE.CN's competition here
MYCO.NE vs SNN.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, SNN.CN has a market cap of 6.1M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while SNN.CN trades at CA$0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas SNN.CN's P/E ratio is -0.15. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to SNN.CN's ROE of -0.49%. Regarding short-term risk, MYCO.NE and SNN.CN have similar daily volatility (0.00).Check SNN.CN's competition here
MYCO.NE vs WLLW.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, WLLW.TO has a market cap of 5.2M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while WLLW.TO trades at CA$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas WLLW.TO's P/E ratio is -0.22. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to WLLW.TO's ROE of -0.30%. Regarding short-term risk, MYCO.NE is less volatile compared to WLLW.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check WLLW.TO's competition here
MYCO.NE vs BCBC.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, BCBC.CN has a market cap of 5M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while BCBC.CN trades at CA$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas BCBC.CN's P/E ratio is -2.00. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to BCBC.CN's ROE of -1.93%. Regarding short-term risk, MYCO.NE is less volatile compared to BCBC.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check BCBC.CN's competition here
MYCO.NE vs TGIF.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, TGIF.CN has a market cap of 5M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while TGIF.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas TGIF.CN's P/E ratio is -0.50. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to TGIF.CN's ROE of -0.12%. Regarding short-term risk, MYCO.NE and TGIF.CN have similar daily volatility (0.00).Check TGIF.CN's competition here
MYCO.NE vs CANN.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CANN.CN has a market cap of 4.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while CANN.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CANN.CN's P/E ratio is -0.25. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to CANN.CN's ROE of -0.66%. Regarding short-term risk, MYCO.NE and CANN.CN have similar daily volatility (0.00).Check CANN.CN's competition here
MYCO.NE vs BHNG.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, BHNG.CN has a market cap of 4.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while BHNG.CN trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas BHNG.CN's P/E ratio is -1.00. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to BHNG.CN's ROE of +4.01%. Regarding short-term risk, MYCO.NE and BHNG.CN have similar daily volatility (0.00).Check BHNG.CN's competition here
MYCO.NE vs FFNT.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, FFNT.CN has a market cap of 4.6M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while FFNT.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas FFNT.CN's P/E ratio is -0.03. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to FFNT.CN's ROE of +7.89%. Regarding short-term risk, MYCO.NE and FFNT.CN have similar daily volatility (0.00).Check FFNT.CN's competition here
MYCO.NE vs LUFF.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, LUFF.CN has a market cap of 4M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while LUFF.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas LUFF.CN's P/E ratio is -0.56. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to LUFF.CN's ROE of -0.32%. Regarding short-term risk, Volatility data is not available for a full comparison. MYCO.NE has daily volatility of 0.00 and LUFF.CN has daily volatility of N/A.Check LUFF.CN's competition here
MYCO.NE vs FH.NE Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, FH.NE has a market cap of 3.9M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while FH.NE trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas FH.NE's P/E ratio is -0.50. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to FH.NE's ROE of -2.83%. Regarding short-term risk, MYCO.NE is less volatile compared to FH.NE. This indicates potentially lower risk in terms of short-term price fluctuations for MYCO.NE.Check FH.NE's competition here
MYCO.NE vs BAMM.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, BAMM.CN has a market cap of 3.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while BAMM.CN trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas BAMM.CN's P/E ratio is -0.12. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to BAMM.CN's ROE of +65.27%. Regarding short-term risk, MYCO.NE and BAMM.CN have similar daily volatility (0.00).Check BAMM.CN's competition here
MYCO.NE vs TILT.NE Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, TILT.NE has a market cap of 3.5M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while TILT.NE trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas TILT.NE's P/E ratio is -0.03. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to TILT.NE's ROE of +2.18%. Regarding short-term risk, MYCO.NE and TILT.NE have similar daily volatility (0.00).Check TILT.NE's competition here
MYCO.NE vs RMC.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, RMC.CN has a market cap of 3.4M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while RMC.CN trades at CA$0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas RMC.CN's P/E ratio is -4.00. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to RMC.CN's ROE of +1.25%. Regarding short-term risk, MYCO.NE and RMC.CN have similar daily volatility (0.00).Check RMC.CN's competition here
MYCO.NE vs THC.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, THC.CN has a market cap of 3.3M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while THC.CN trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas THC.CN's P/E ratio is -1.00. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to THC.CN's ROE of -0.37%. Regarding short-term risk, MYCO.NE and THC.CN have similar daily volatility (0.00).Check THC.CN's competition here
MYCO.NE vs NBUD.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, NBUD.CN has a market cap of 3.2M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while NBUD.CN trades at CA$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas NBUD.CN's P/E ratio is -1.25. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to NBUD.CN's ROE of -0.27%. Regarding short-term risk, MYCO.NE and NBUD.CN have similar daily volatility (0.00).Check NBUD.CN's competition here
MYCO.NE vs MSVN.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, MSVN.CN has a market cap of 2.9M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while MSVN.CN trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas MSVN.CN's P/E ratio is -0.06. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to MSVN.CN's ROE of +19.42%. Regarding short-term risk, MYCO.NE and MSVN.CN have similar daily volatility (0.00).Check MSVN.CN's competition here
MYCO.NE vs AREV.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, AREV.CN has a market cap of 2.9M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while AREV.CN trades at CA$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas AREV.CN's P/E ratio is -2.25. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to AREV.CN's ROE of +2.76%. Regarding short-term risk, MYCO.NE and AREV.CN have similar daily volatility (0.00).Check AREV.CN's competition here
MYCO.NE vs ASP.TO Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, ASP.TO has a market cap of 2.8M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while ASP.TO trades at CA$0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas ASP.TO's P/E ratio is -0.08. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to ASP.TO's ROE of +3.10%. Regarding short-term risk, MYCO.NE and ASP.TO have similar daily volatility (0.00).Check ASP.TO's competition here
MYCO.NE vs CDVA.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CDVA.CN has a market cap of 2.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while CDVA.CN trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CDVA.CN's P/E ratio is -1.25. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to CDVA.CN's ROE of +0.50%. Regarding short-term risk, MYCO.NE and CDVA.CN have similar daily volatility (0.00).Check CDVA.CN's competition here
MYCO.NE vs CFT.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CFT.CN has a market cap of 2.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while CFT.CN trades at CA$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CFT.CN's P/E ratio is -0.13. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to CFT.CN's ROE of -2.12%. Regarding short-term risk, MYCO.NE and CFT.CN have similar daily volatility (0.00).Check CFT.CN's competition here
MYCO.NE vs IPOT.CN Comparison April 2026
MYCO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, IPOT.CN has a market cap of 2.6M. Regarding current trading prices, MYCO.NE is priced at CA$0.35, while IPOT.CN trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas IPOT.CN's P/E ratio is -0.50. In terms of profitability, MYCO.NE's ROE is -0.01%, compared to IPOT.CN's ROE of -2.22%. Regarding short-term risk, MYCO.NE and IPOT.CN have similar daily volatility (0.00).Check IPOT.CN's competition here